Advanced Generation Folate Therapy-EnLyte-Patented To Treat High Homocysteine, a Condition Associated with PTSD, Announces JayMac Pharmaceuticals, LLC
| PR Web |
(PRWEB)
PTSD (Post Traumatic Stress Disorder) among military men and women is prevalent, with over 10,000 new cases diagnosed each year, some requiring hospitalization. A link between PTSD and high homocysteine – an amino acid – has been validated in many studies. Many things can contribute to high homocysteine, including extreme stress, as would be expected in PTSD, and genetic issues such as the MTHFR polymorphism. A critical combination of B vitamins and co-factors is needed to keep homocysteine in a healthy range, and when elevated, it can lead to cardiovascular disease, stroke, dementia, and a host of other health problems.
One study published by Levine, et al. in Depression and Anxiety found "the duration of PTSD was found to predict serum homocysteine levels. Our results suggest that elevated levels of homocysteine in male patients with PTSD may be related to pathophysiological aspects associated with the chronicity of this disorder." Another study published by Jendricko, et al. in Progress in NeuroPsychopharmacology & Biological Psychiatry found homocysteine levels significantly higher in men with PTSD than in those without.
Antidepresssants and cognitive therapy are the most common ways to treat this disorder. Adding a homocysteine-lowering agent to this regimen would help improve symptoms and overall health long term. There is only one patented drug containing all of the necessary ingredients to lower homocysteine – EnLyte with Delta Folate. This is a new, natural, advanced generation folate therapy containing all natural, unique, and reduced folates and co-factors, as well as other minerals for overall brain health. It may be used alone or added to an SSRI/SNRI. With both the depression and hyperhomocysteinemia indications, this new drug has huge potential to assist in the military arena:
• Treat PTSD Symptoms and Lower Homocysteine: It would reduce homocysteine levels and would improve clinical drug outcomes when added to an SSRI/SNRI
• Provide a safe, effective, and natural option to treat depression without side effects
• Pregnancy category A
•
• DMLSS coverage
•
To learn more, visit http://www.EnlyteRx.Com.
Read the full story at http://www.prweb.com/releases/2014/07/prweb12044149.htm
| Copyright: | (c) 2014 PRWEB.COM Newswire |
| Wordcount: | 380 |



Doing right by ‘Lady Justice’: Restoration planned for statue, dome
Advisor News
- Women say their advisors respect them, but talk down to them
- How PEPs compare with traditional 401(k)s
- Allianz studies why 42% of Americans retire sooner than expected
- Why advisors should be talking about life settlements
- Millennials are ready to bring their advisor to the family table
More Advisor NewsAnnuity News
- NAIC regulators continue pushing for annuity illustration updates
- Wink: Flat first-quarter annuity sales fall just short of $100B
- 26North Re Agrees to Acquire 100% of Independent Insurance Group
- Matthew Michelini named Athene president, with an eye on annuity growth
- Lincoln Financial Announces Executive Leadership Transitions
More Annuity NewsHealth/Employee Benefits News
- Presbyterian announces layoffs, ending Medicare Advantage plans
- Franklin County Hiring Tax Assessment Specialist I
- New Findings on Soft Tissue Sarcomas from National Cancer Center Research Institute Summarized (Differences Among Genomic Profiling Tests for Bone and Soft-Tissue Sarcomas in a Universal Health Insurance System): Oncology – Soft Tissue Sarcomas
- New Clinical Oncology Findings from Basit Chaudhry and Co-Authors Described (Biosimilar adoption and provider performance in Medicare value-based payment models): Clinical Oncology
- Arizona AG Mayes accuses health insurance companies of price fixing
More Health/Employee Benefits NewsLife Insurance News
- Prudential announces more layoffs as insurer continues to restructure
- Pradip Patiath Joins Securian Financial Board of Directors
- Over $107 million in life insurance benefits located for Tennesseans in 2025
- Study Data from National Institutes of Health Provide New Insights into Law and the Biosciences (Taking actuarial fairness seriously: what is required for the ethical use of genetics in insurance?): Legal Issues – Law and the Biosciences
- 26North Re Agrees to Acquire 100% of Independent Insurance Group
More Life Insurance News